Selgantolimod

Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection[1][2][3].

Product Specifications

CAS Number

[2004677-13-6]

Product Name Alternative

GS-9688

UNSPSC

12352005

Target

HBV; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/selgantolimod.html

Purity

98.18

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

C[C@@](CCCC)(CO)NC1=NC(N)=NC2=C1N=CC(F)=C2

Molecular Formula

C14H20FN5O

Molecular Weight

293.34

References & Citations

[1]Jules Levin. Efficacy and Safety of Oral TLR8 Agonist Selgantolimod in Virally Suppressed Adult Patients With Chronic Hepatitis B: a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. 2019 Nov 8-12.|[2]Benjamin Ryan. Selgantolimod Shows Promise as Treatment for Hepatitis B. November 18, 2019.|[3]Romas Geleziunas, et al. Modulators of toll-like receptors for the treatment of hiv. US20170071944A1.